Biotech · Public company · La Jolla, CA, US
Inhibrx Biosciences, Inc.
Ticker INBX · SEC CIK 0002007919
Track this companyFree. Adds Inhibrx Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials75 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline18
- INBRX-106Phase 3 · Head and Neck Squamous Cell Carcinoma (HNSCC)ClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Head and Neck Squamous Cell Carcinoma (HNSCC)ClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin AUC-5Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin AUC-6Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- INBRX-106 - Hexavalent OX40 agonist antibodyPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- INBRX-109Phase 2 · Conventional ChondrosarcomaClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab 200 mgPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab 400 mgPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Pemetrexed 500 mg/m2Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- carboplatinPhase 1 · Ewing SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- INBRX-101/rhAAT-FcPhase 1 · Alpha-1 Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- INBRX-105 - PDL1x41BB antibodyPhase 1 · Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- INBRX-109Phase 1 · Ewing SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- IrinotecanPhase 1 · Ewing SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- LeucovorinPhase 1 · Ewing SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- pemetrexedPhase 1 · Ewing SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- TemozolomidePhase 1 · Ewing SarcomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC PatientsPHASE2 · RECRUITING · started Sep 5, 2024ClinicalTrials.gov NCT06353997 · fetched Nov 12, 2026
- Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)PHASE2_PHASE3 · RECRUITING · started May 14, 2024ClinicalTrials.gov NCT06295731 · fetched Nov 12, 2026
- Study of INBRX-109 in Conventional ChondrosarcomaPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 23, 2021ClinicalTrials.gov NCT04950075 · fetched Nov 12, 2026
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)PHASE1_PHASE2 · RECRUITING · started Dec 10, 2019ClinicalTrials.gov NCT04198766 · fetched Nov 12, 2026
- Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin DeficiencyPHASE1 · COMPLETED · started Jul 19, 2019ClinicalTrials.gov NCT03815396 · fetched Nov 12, 2026
- Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerPHASE1 · TERMINATED · started Jan 30, 2019ClinicalTrials.gov NCT03809624 · fetched Nov 12, 2026
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasPHASE1 · RECRUITING · started Oct 8, 2018ClinicalTrials.gov NCT03715933 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 19, 2026 · fetched Nov 12, 2026